Core Insights - Klotho Neuroscience, Inc. is partnering with leading researchers from the Okinawa Research Center for Longevity Science to explore the role of the Klotho gene in promoting longevity and reducing neurodegenerative diseases [1][2][3] Company Overview - Klotho Neuroscience, Inc. (NASDAQ: KLTO) focuses on developing cell and gene therapies targeting neurological conditions such as ALS, Alzheimer's Disease, and Parkinson's Disease [1][4] - The company utilizes a patented form of the Klotho gene, specifically the secreted alpha-Klotho protein isoform (s-KL), in its innovative therapies [4] Research and Development - Preliminary data from ORCLS suggests that the alpha-Klotho gene and its protein isoform may contribute to healthy longevity, with decreased levels correlating with various age-related diseases [2][3] - The partnership will analyze blood samples from centenarians to assess the Klotho protein's role in longevity and its potential protective effects against neurodegenerative disorders [3][4] Historical Context - Okinawa is recognized as the original Blue Zone, known for its high concentration of centenarians, validated by extensive research from ORCLS over the past five decades [2][3] - ORCLS has a history of significant discoveries in human aging, including the identification of longevity genes and their translation from model organisms to humans [3]

Key highlights of the announcement include: NEW YORK, June 18, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. (NASDAQ: KLTO) ("Klotho," "KLTO," or the "Company") today announced that on June 13, 2025, it entered into a Termination and Release Agreement with SkyBell Technologies, Inc. ("SkyBell"), formally ending the Share Exchange Agreement previously executed on March 26, 2025. Investor Contact and Corporate Communications - Jeffrey LeBlanc, CFO [email protected] Website: www.klothoneuro.com Forward-Looki ...

盘前市场动向 | 德国DAX30 | 24,068.83 | 24,180.13 | 23,964.77 | -104.96 | -0.43% | | --- | --- | --- | --- | --- | --- | | 器 英国富时100 | 8,866.55 | 8,880.15 | 8,847.78 | +34.27 | +0.39% | | 法国CAC40 | 7,782.62 | 7,815.44 | 7.769.51 | -8.85 | -0.11% | | □ 欧洲斯托克50 | 5,409.45 | 5,428.25 | 5,395.85 | -12.07 | -0.22% | 3. 截至发稿，WTI原油涨0.37%，报65.53美元/桶。布伦特原油涨0.36%，报67.28美元/桶。 | 트 WTI原油 | 2025年7月 | 65.53 | 65.68 | 65.16 | +0.24 | +0.37% | | --- | --- | --- | --- | --- | --- | --- | | 疆 伦敦布伦特原油 | 2025年8月 | 67.28 | 67.43 | 66.95 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-41340 KLOTHO NEUROSCIENCES, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or o ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 ACT OF 1934 For the fiscal period ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-41340 KLOTHO NEUROSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 86-2727441 (I.R.S. Employer Iden ...

Core Insights - Klotho Neurosciences, Inc. is set to present at Biotech Showcase 2025, focusing on its innovative therapies for neurodegenerative diseases [1][2] - The company is developing cell and gene therapies targeting ALS, Alzheimer's, and Parkinson's disease, utilizing the Klotho anti-aging gene [2][3] - Klotho Neurosciences has secured exclusive worldwide licenses for its therapeutic approach, covering patents in the USA, Europe, and China [2] Company Overview - Klotho Neurosciences, Inc. specializes in biopharmaceuticals, particularly in cell and gene therapies derived from the Klotho gene [3] - The company’s portfolio includes DNA and RNA therapeutics, genomics-based diagnostics, and clinical-stage programs targeting cancer and autoimmune diseases [3] - Management comprises experienced professionals in biopharmaceutical product development and commercialization [3] Presentation Details - The presentation is scheduled for January 14, 2025, at 3:00 PM PT during J.P. Morgan Healthcare Week [1][2] - Dr. Joseph Sinkule, the Founder, CEO, and Chairman, will discuss the company's advancements and the role of the Klotho gene in treating neurodegenerative diseases [2] - The event is expected to attract over 3,200 healthcare professionals and more than 1,200 investors [1]

NEW YORK, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Klotho Neurosciences, Inc. (NASDAQ: KLTO), a U.S.-based biotechnology company pioneering cell and gene therapies for neurodegenerative and age-related disorders, including ALS, Alzheimer’s, and Parkinson’s, today announced the appointment of Riad El-Dada, former US President of Merck, to its Board of Directors. With decades of leadership in the pharmaceutical industry, Mr. El-Dada brings extensive experience in product development, commercialization, and strategic ...

Financial Performance - Klotho Neurosciences, Inc. reported no revenue for the nine months ended September 30, 2024, and September 30, 2023[125]. - Operating expenses for the three months ended September 30, 2024, were $2,870,932, an increase of $2,747,195 compared to $123,737 for the same period in 2023[126]. - The net loss for the three months ended September 30, 2024, was $2,959,426, compared to a net loss of $144,111 for the same period in 2023, reflecting an increase of $2,815,315[128]. Cash Flow - As of September 30, 2024, the company had cash of $50,895 and an accumulated deficit of approximately $8.5 million[136]. - Net cash used in operating activities for the nine months ended September 30, 2024, was $2,002,358, an increase of approximately $1,755,000 compared to $247,406 for the same period in 2023[132]. - Net cash provided by financing activities for the nine months ended September 30, 2024, was $2,173,942, compared to $250,000 for the same period in 2023[134]. - The company expects net cash used in operating activities to increase in the coming periods until its products generate meaningful revenue[132]. Going Concern - Klotho Neurosciences, Inc. has incurred significant operating losses and negative cash flows from operations since inception, raising concerns about its ability to continue as a going concern[136]. - The company has no off-balance sheet arrangements as of September 30, 2024[137]. Company Classification - Klotho is classified as an "emerging growth company" and intends to take advantage of certain exemptions from reporting requirements[139].

Revenue - The Company reported no revenue for the six months ended June 30, 2024, and June 30, 2023[96]. Operating Expenses - Operating expenses for the three months ended June 30, 2024, were $395,607, an increase of approximately 62% compared to $244,252 for the same period in 2023[97]. - The Company incurred operating expenses of $817,652 for the six months ended June 30, 2024, an increase of approximately 106% from $396,852 for the same period in 2023[98]. Net Loss - The net loss for the three months ended June 30, 2024, was $451,639, representing an increase of approximately 71% from a net loss of $264,389 in the same period of 2023[99]. Cash Flow - Net cash used in operating activities for the six months ended June 30, 2024, was $929,399, an increase of approximately 250% from $265,429 for the same period in 2023[103]. - Net cash provided by financing activities for the six months ended June 30, 2024, was $1,895,424, a significant increase of approximately 658% compared to $250,000 in the same period of 2023[105]. - The increase in cash used in investing activities for the six months ended June 30, 2024, was approximately 517%, totaling $123,497 compared to $20,000 in the same period of 2023[104]. Liquidity and Financial Position - As of June 30, 2024, the Company had cash of $845,336 and an accumulated deficit of approximately $5.5 million[107]. - The Company has incurred significant professional costs and transaction costs related to the Business Combination, impacting its liquidity[106]. - The Company expects net cash from operating activities to remain negative until products generate meaningful revenue[103].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Delaware 86-2727441 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) Title of each class Trading Symbol(s) Name of each exchange on which registered Units RWODU The Nasdaq Stock Market LLC Common Stock RWOD The Nasdaq Stock Market LLC Warrants RWODW The Nasdaq Stock Market LLC Rights RWODR The Nasdaq Stock Market LLC FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SE ...